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Summary Despite considerable advances in pharmacological, surgical and technology-based
cardiovascular therapy, left ventricular dysfunction and heart failure are increasingly prevalentHeart failure;
Left ventricular
dysfunction
health problems. Recent studies suggest that angiogenic gene therapy can restore perfusion in
ischaemic myocardial tissue, and that the transfer of nonangiogenic genes may correct defects
in calcium handling that contribute to abnormal contractile function in patients with heart fail-
ure; however, large clinical trials of gene therapy for treatment of left ventricular dysfunction
and heart failure have yet to be completed, and only a small number of genes have been eval-
uated in patients. Researchers continue to investigate new genes, combinations of genes and
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cell-derived factor-1; SERCA2a, sarcoplasmic reticulum calcium adenosine triphosphatase; Shh, sonic hedgehog; VEGF, vascular endothe-
lial growth factor; CXCL12, chemokine ligand 12; bFGF, basic FGF; AdVEGF-121, adenovial VEGF-121; AGENT, Angiogenic Gene Therapy;
AdFGF-4, adenoviral FGF-4; CUPID, calcium upregulation percutaneous administration of gene therapy in cardiac disease.
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approaches that combine gene and cell therapy, and to develop novel expression vectors and
delivery systems; collectively, these reﬁnements promise to improve both patient response and
safety.
© 2010 Elsevier Masson SAS. All rights reserved.
MOTS CLÉS
Thérapie génique ;
Insufﬁsance
cardiaque ;
Dysfunction
ventriculaire gauche
Résumé Malgré les considérables avancées dans les traitements médicamenteux, interven-
tionnels et chirurgicaux, la dysfunction ventriculaire gauche et l’insufﬁsance cardiaque restent
d’importants problèmes de santé publique. De récentes études suggèrent que la thérapie
génique angiogénique peut restorer une perfusion du tissu myocardique ischémique et que le
transfert de gènes non angiogéniques peut corriger les anomalies du transport calcique qui con-
tribuent aux défauts de contraction myocardique chez les patients avec insufﬁsance cardiaque.
Cependant, de grandes études cliniques de thérapie génique pour le traitement de la dysfunc-
tion ventriculaire gauche et de l’insufﬁsance cardiaque sont en attente. Seul un petit nombre
de gènes a été étudié à ce jour chez l’homme. Les chercheurs poursuivent les travaux avec de
nouveaux gènes, des combinaisons de gènes, des approches qui associent thérapies cellulaires
et géniques, ainsi qu’avec le développement de nouveaux vecteurs et systèmes de délivrance.
Le but est d’améliorer le bénéﬁce pour les patients en s’assurant de la bonne tolérance de ces
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ackground
VD and heart failure are increasingly important health
roblems despite considerable advances in pharmacological,
urgical and technological approaches to treatment. Heart
ailure is the leading medical cause of hospitalization and is
xpected to cost the USA health care system $37.2 billion in
irect and indirect expenses in 2009 [1]. The most common
ause of LVD is coronary artery disease, followed by hyper-
ension and valvular disease. Heart failure, which often
evelops in patients who survive myocardial infarction, is
debilitating disease with high morbidity and can lead to
requent hospital re-admissions. The prognosis for patients
ith chronic heart failure remains poor. Nonpharmacologi-
al therapies, such as heart transplantation and the use of
mplantable left ventricular assist devices, are considered
ppropriate only in later stages of disease progression and,
onsequently, are considered for a very small fraction of
ounger patients.
The impaired cardiac contractile function associated
ith heart failure can be attributed to declines in per-
usion and to unfavourable cardiac remodelling. Because
ene therapy is designed to restore perfusion, and newer
reatments may also target abnormalities in the contrac-
ile function of viable cardiomyocytes, it may be considered
promising alternative for the treatment of LVD and
eart failure. Here, we describe several genes that are
urrently under investigation, the advantages and disad-
antages of the vectors and delivery routes that are used
ost frequently, and the implications of ﬁndings from pre-
linical and early clinical trials of cardiovascular gene
herapy.ene candidates
umerous proteins, growth factors, cytokines and calcium-
ransport regulators have been the focus of angiogenic and
p
i
ﬁ
p
es droits réservés.
yogenic research. Several genes have been investigated
n vitro and in animal models, and the promising results of
hese studies have justiﬁed the ﬁrst clinical evaluations. A
umber of these genes are described below, but only a few
ave been used clinically.
ascular endothelial growth factor
EGF, which could be considered the prototype for angio-
enic gene therapy [2], has been shown to improve LVD in
nimal models of both ischaemic [2] and pacing-induced
eart failure [3]. VEGF-A (also called VEGF-1) was ﬁrst
iscovered in 1989 [4] and is the founding member of
he VEGF protein family. VEGF-A is upregulated during
athological vessel growth [5], but it possesses a diverse
rray of pro-angiogenic properties and is the isoform used
ost frequently in gene therapy. Several VEGF-A deriva-
ives, each containing a different number of amino acids
e.g., VEGF-121, VEGF-165, VEGF-189, and VEGF-206), can
nduce angiogenesis in animal models [6]; their solubili-
ies and binding characteristics (e.g., to heparin and the
xtracellular matrix) differ, which inﬂuences their ability
o interact with target cells and, presumably, alters their
ngiogenic potency. VEGF-165 is the most promising for
se in angiogenic therapy, because it is the most potent
100-fold more potent than VEGF-121) and can induce the
evelopmental gradients required to pattern vessel growth
7].
ibroblast growth factor
he FGF family includes 23 members, of which acidic FGF
FGF-1) and bFGF or FGF-2 are the best characterized.
he biological activity of FGF is not well understood. FGF
roteins are potent mitogens for a variety of cell types,
ncluding endothelial cells, vascular smooth muscle cells and
broblasts, and FGF secretion stimulates the synthesis of
roteases that contribute to angiogenesis by digesting the
xtracellular matrix. Unlike VEGF, FGF-1 and FGF-2 are not
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crucial for embryogenesis, and because they lack a secretory
signal sequence, they enter the extracellular space only pas-
sively after cell damage. Nevertheless, both have been used
successfully to induce angiogenesis [8], and the secreted
FGF isoforms, such as FGF-4 and FGF-5, may have even more
therapeutic potential.
Hypoxia-inducible factor
The metabolic stimuli associated with hypoxia and
ischaemia induce expression of a variety of transcription
factors that stimulate angiogenesis, and researchers have
begun to investigate the genetic transfer of these fac-
tors as an alternative to growth-factor-based gene therapy.
Because interactions between HIFs and hypoxia response
elements trigger an ‘‘angiogenesis programme’’ by upreg-
ulating the expression of a number of growth factors and
cytokines simultaneously, the therapeutic administration of
HIF could enhance vascular growth by mimicking the natural
angiogenic response. HIF1-alpha regulates the expression of
SDF-1, which is critically involved both in the mobilization
of angiogenic progenitor cells from the bone marrow to the
peripheral circulation and in the recruitment of mobilized
cells to ischaemic tissue [9]. However, HIF1-alpha can also
induce cell death and may be signiﬁcantly less potent than
VEGF [10].
Sonic hedgehog
Recent experiments performed in our laboratory indicate
that the embryonic hedgehog signalling pathway can be
reactivated to combat ischaemia in adult mammals. Recom-
binant Shh protein induces a robust angiogenic effect by
upregulating multiple angiogenic factors, including VEGF, in
interstitial mesenchymal cells [11], and genetic transfer of
Shh enhances the regeneration of ischaemic myocardium
by inducing the expression of trophic factors, such as
SDF-1, which increases the recruitment and incorporation
of bone marrow-derived progenitor cells into the growing
vasculature [12]. We have also shown that Gli3, a tran-
scription factor targeted by Shh during hedgehog signalling,
is strongly upregulated in the ischaemic tissue of adult
mammals and may have a favourable effect on myogene-
sis and angiogenesis after an ischaemic insult [13]. Because
Shh appears to trigger a cascade of pro-angiogenic factors,
it may be particularly effective for angiogenic gene ther-
apy.
Stromal cell-derived factor-1
SDF-1 (also called CXC CXCL12) is a 68-amino-acid protein of
the CXC chemokine family. Two isoforms, SDF-1-alpha and
SDF-1-beta, are encoded as splice variants of a single gene
and are expressed by both endothelial cells and stem cells.
The growth factor activity of SDF-1 has most often been
linked to lymphopoiesis and myelopoiesis [14], but inter-
actions between SDF-1 and its receptor CXCR4 also regulate
progenitor cell trafﬁcking, and SDF-1-alpha is essential for
the recruitment of stem and progenitor cells to ischaemic
tissue [15].
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actors that regulate calcium transport
bnormalities in the function of molecules responsible for
he rhythmic release and uptake of Ca2+ ions in myocytes
ontribute to impaired cardiac contractility in patients with
eart failure [16], and because myocardial contractility is
ependent on ventricular Ca2+ handling, genetic modiﬁca-
ion of these molecules could be a viable approach for
reatment of heart failure. One of the key Ca2+ handling
bnormalities in both humans and experimental models of
eart failure is caused by a defect in sarcoplasmic reticulum
unction, and a large body of experimental evidence indi-
ates that SERCA2a plays an important role in the progres-
ion of dilated cardiomyopathy. SERCA2a activity is known to
ecline in late-stage heart failure, and SERCA2a protein and
essenger RNA levels are reduced in cardiac tissue isolated
rom the failing hearts of patients and animals with heart
ailure [17,18]. Furthermore, gene therapy with a pseu-
ophosphorylated mutant of phospholamban, the principal
egulator of SERCA2a, treated cardiomyopathy in hamsters
nd infarction-induced heart failure in rats successfully for 6
onths or more [19,20]. Preclinical studies also indicate that
ncreases in cardiac adenylyl cyclase content improve left
entricular function, attenuate deleterious remodelling and
educe mortality in both heart failure and acute-infarction
odels. Investigations of adenylyl cyclase type 6 gene
ransfer have progressed from studies in cultured cardiac
yocytes to animal models of heart failure [21].
ene delivery
ectors
nlike protein administration, gene therapy can lead to
igh, sustained protein levels; however, the effectiveness of
ene transfer depends on the transfection efﬁciency— the
mount of the gene internalized by cells in the target
issue—and the magnitude and endurance of subsequent
xpression. The cellular insertion and intracellular trafﬁck-
ng of the transgene is facilitated by vectors, which can
e categorized as viral or nonviral. Nonviral plasmid vec-
ors were used in early investigations because they are
nexpensive, easily constructed, and generally considered
afe; plasmid vectors do not initiate inﬂammation or an
mmune response and incur no risk of insertional mutage-
esis. Plasmid DNA is taken up effectively and expressed
y all mammalian cell types, including cardiomyocytes, in
ivo; however, the transfection efﬁciency of plasmid vectors
as low in randomized, controlled trials [22,23]. Never-
heless, plasmid vectors could be useful when short-term
odiﬁcation of gene expression may be beneﬁcial, such as
mmediately after an acute cardiac event, or for initiating
echanisms that lead to progenitor cell recruitment and to
he activation of resident stem cells. More recently, small
nterfering RNAs have become popular for inhibition studies
nd could provide a new option for nonviral gene manipu-
ation; very high transfection efﬁciency can be achieved by
dministering decoy receptors or antibodies that circumvent
locking factors in cardiovascular tissue.
The viral vectors used most frequently for cardiovas-
ular gene therapy are adenoviruses and AAVs; retroviral
4 J. Roncalli et al.
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Table 1 Therapeutic goals and underlying mechanisms
for the treatment of left ventricular dysfunction and
heart failure.
Therapeutic goal Mechanisms
Vascularization Angiogenesis
Vasculogenesis
Arteriogenesis
Lymphangiogenesis
Endothelial function
Endothelial repair
Re-endothelialization
SMC proliferation matrix
Production/degradation
Apoptosis
Cardiomyogenesis Cardiomyocyte homeostasis
Cellular contraction
Calcium
Hypertrophy
Fibrosis
Apoptosis
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ectors were used in early studies, but their popularity
as declined because of safety concerns. Compared with
lasmid transfection, viral transfection into vessel walls
nd heart muscle is much more efﬁcient [24], and virally
ransfected genes are typically expressed for a longer
eriod of time—AAV-transfected genes can be expressed
or months—although the duration varies depending on the
irus used. In addition, viral vectors typically infect only
limited number of cell types, and this speciﬁcity (i.e.,
ropism) can be advantageous for cardiovascular therapy.
denoviruses seem particularly effective for transfecting
ardiomyocytes [25], and naturally occurring tropisms for
ascular smooth muscle cells and cardiomyocytes are among
he more useful characteristics of AAVs. However, viral vec-
ors can generate an inﬂammatory or immunogenic response
nd may integrate into the cellular genome, which could
ncrease cancer risk. Nevertheless, adenoviruses have a
ood safety record in cardiovascular clinical trials [22,26],
nd the likelihood of inﬂammation, immunogenicity and
ost-genome integration varies depending on the vector
sed.
outes of administration
linical acceptance of gene therapy as a routine treat-
ent option will require the development of standardized,
ractical delivery systems and techniques for delivering
he gene to the tissues targeted most frequently, such as
he myocardium and blood vessels. Genes can be injected
irectly into the targeted tissue for treatment of periph-
ral disease, but local delivery to the heart used to require
pen-chest surgery or thoracoscopy. Intracoronary adminis-
ration or catheter-based delivery systems (e.g., navigation
nd catheter mapping technology) for transendocardial gene
elivery to the myocardium are much less invasive and more
easible for patients with LVD and heart failure [27].
ene therapy for ischaemic or
onischaemic left ventricular dysfunction
nd heart failure
o date, most cardiovascular gene therapies are designed to
ncrease vascular growth and perfusion in ischaemic tissue
i.e., therapeutic angiogenesis) [28]; however, declines in
eart function can also be attributable to adverse cardiac
emodelling, which evolves from a wide variety of biological
hanges, including the loss of functional cardiomyocytes and
isorganization of the contractile response. These abnor-
alities may be suitable targets for nonangiogenic gene
herapies designed to prevent or suppress the development
f heart failure (Table 1).
ngiogenic gene therapy
ong-term survival after myocardial infarction is now the
ost common cause of chronic heart failure, and despite
igniﬁcant medical advances, postischaemic heart failure
emains a primary contributor to morbidity and mortality in
he western world [29]. One of the primary goals for treating
eart failure is improving perfusion in the ischaemic region,
s
f
o
PSMC: smooth muscle cell.
hereby preserving functional tissue and (perhaps) restor-
ng function in viable, but dormant (i.e., ‘‘hibernating’’)
yocardium. Several laboratories have demonstrated that
herapeutic vascular growth can be achieved in vivo by
he genetic transfer of cytokines [2,30]. VEGF and, to a
esser extent, FGF are the most frequently studied and best-
eveloped cytokines used in the clinical setting.
In the REVASC trial [31], 67 patients with coronary
rtery disease, severe angina and no conventional options
or revascularization were randomized to receive direct
ntramyocardial gene transfer of adenoviral VEGF-121
AdVEGF-121) via minithoracotomy or to continue receiving
aximal medical treatment. Exercise time, the primary efﬁ-
acy endpoint, was signiﬁcantly greater in patients treated
ith AdVEGF-121 than in the control group (P = 0.026), and
here was no signiﬁcant difference between the two treat-
ent groups in overall adverse event occurrence. In a phase
study, ﬁve ‘no-option’ patients with occlusive coronary
rtery disease and mild LVD received VEGF-165 plasmid
NA (pVEGF-165) via intramyocardial injection after tho-
acotomy. Patients experienced improvements in collateral
essel growth, myocardial perfusion, myocardial contractile
unction and clinical status [32]; the same treatment was
ssociated with signiﬁcant declines in mean ischaemic area
n patients with chronic myocardial ischaemia and moder-
te LVD (mean ejection fraction, 44± 4%) [33,34]. In the
uroinject One trial, 80 ‘no-option’ patients with severe,
table, ischaemic heart disease received pVEGF-165 (0.5mg)
r a placebo plasmid; the therapy appeared to be safe and
as associated with improved regional wall motion and a
avourable anti-ischaemic effect [23], but did not improve
igniﬁcantly stress-induced abnormalities in myocardial per-
usion.
The AGENT trials evaluated the intracoronary injection
f AdFGF-4 in patients with stable coronary artery disease.
ositive trends were observed in the two small phase 1/2
473
rently underway to determine whether a type 5 adenovirus
encoding this gene can be administered safely and is poten-
tially beneﬁcial in patients with congestive heart failure.
Combination therapy
As the characterization of individual gene therapies
becomes more complete, preclinical investigations designed
to identify the potential complementary or synergistic
effects achieved with combinations of therapies have been
initiated. The outcomes of these studies will be determined,
in part, by the same variables that inﬂuence the effective-
ness of single-gene therapy, including the model species,
the delivery vector, the organ and disease treated, and the
genes delivered.
Two (or more) co-injected genes may not be expressed
in the intended ratio, because one of the vectors could be
preferentially silenced or removed [40]. Thus, therapeutic
approaches that rely on combinations of genes will require
the development of a gene transfer system that ensures
the stable co-expression of both molecules. One system for
inducing stable gene expression involves the use of IRESs.
IRESs are structural elements located in the 5′ untranslated
region of several mRNAs, where they permit the recruit-
ment of translational machinery. These elements can be
used to create expression cassettes that code for combi-
nations of genes within a single mRNA sequence (Fig. 1).
In a murine hindlimb ischaemia model, Rayssac et al. [41]
showed that the expression of FGF-2 and Cyr61 was more
stable when both genes were encoded by a single IRES-
Figure 1. Combining gene therapies with an IRES-based system.
With standard nonviral vectors, therapy that combines two genes
(top and middle) requires the administration of two independent
plasmids; however, the genes may not be expressed in the intended
ratio, because one of the vectors could be preferentially silenced
or removed. In an IRES-based system (bottom), a single vector can
encode two (or more) genes separated by an IRES, thereby main-
taining the intended expression ratio and decreasing the risk ofGene therapy and heart failure
trials (AGENT 1 and 2) [35,36], but the larger, double-blind,
placebo-controlled trials (AGENT 3 and 4) were halted when
an interim analysis of data from the AGENT 3 trial indicated
that the primary endpoint would not reach statistical sig-
niﬁcance. The interim analysis found no signiﬁcant safety
concerns, and pooled analyses of AGENT 3 and AGENT 4
data identiﬁed a sex-speciﬁc beneﬁt: compared with women
in the placebo treatment group, women who were treated
with AdFGF-4 displayed signiﬁcantly greater improvement
in clinical status [37].
Collectively, the results of the REVASC (AdVEGF-121),
Euroinject One (phVEGF-165) and AGENT trials (AdFGF-
4) indicate that AdVEGF and AdFGF therapy are safe and
may induce neovascularization in patients with myocardial
ischaemia who lack options for revascularization surgery but
have relatively preserved left ventricular ejection fractions;
however, only limited improvements were observed in many
cardiovascular measures. Longer follow-up periods may be
necessary, and because heart failure is a progressive disease,
patients may need to receive multiple treatments before
signiﬁcant beneﬁts are observed in global cardiovascular
variables.
Nonangiogenic gene therapy
Although most studies of cardiovascular gene therapy have
investigated the use of angiogenic factors, many other genes
are potential candidates for the treatment of heart fail-
ure. Gene therapy with recombinant AAV vectors coding for
the expression of SERCA2a, which declines in patients with
heart failure, was well tolerated in both small- and large-
animal heart failure models, and restoration of SERCA2a
levels to normal levels led to a signiﬁcant improvement in
cardiac function. These ﬁndings prompted initiation of the
ﬁrst-in-human phase 1/2 CUPID trial [38]. In the open-label
portion of this ongoing study, nine patients with advanced
heart failure received a single intracoronary infusion of
recombinant AAV SERCA2a; the treatment was associated
with an acceptable safety proﬁle and with improvements in
a number of symptomatic and functional variables, which
supports initiation of the ensuing phase 2, double-blind,
placebo-controlled study. A second, randomized, double-
blind study (ClinicalTrials.gov identiﬁer: NCT00534703) is
investigating the safety and feasibility of SERCA2a gene
therapy when delivered with the AAV6 vector and driven
by the cytomegalovirus promoter (AAV6-CMV-SERCA2a). Six-
teen patients with advanced heart failure who have received
a left ventricular assist device will be randomized to receive
AAV6-CMV-SERCA2a or placebo infusion into the coronary
arteries, and the recovery of contractile function will be
assessed during attempts to wean patients from the left
ventricular assist device. The results will be assessed in con-
junction with two studies in the USA: one of which delivers
the same vector via direct injection into the myocardium
during left ventricular assist device insertion, and another
in which an AAV1-CMV-SERCA2a vector is administered per-
cutaneously.A substantial amount of data accumulated during the past
several years suggests that adenylyl cyclase 6 expression
may have unexpected but pronounced favourable effects
for the treatment of cardiovascular disease [39]. A clinical
study (ClinicalTrials.gov identiﬁer: NCT00787059) is cur-
adverse effects associated with the administration of several vec-
tors. Collectively, these effects could substantially improve the
risk-to-beneﬁt ratio, which is of primary importance for poten-
tial clinical applications. IRES: internal ribosome entry site; pCMV:
cytomegalovirus promoter.
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ased vector rather than by two independent vectors, and
ascular growth was more abundant, even though FGF-2
nd Cyr61 protein levels were 5- to 10-fold lower in ani-
als treated with the IRES vector. Furthermore, the vector
ncoding Cyr61 alone accelerates B16 melanoma growth in
ice, whereas the IRES-based vector was not associated
ith carcinogenic effects. Thus, the risk-to-beneﬁt ratio
f this system appears to be very low and could likely be
educed even further, because many IRESs are tissue and/or
ontext speciﬁc, and a third or fourth factor could be added
o promote functional vessel growth with still lower doses
f angiogenic factors.
Formation of a functional vascular network is a complex
rocess involving multiple angiogenic factors that induce
oth capillary sprouting and the growth and remodelling of
ollateral arteries [42]. Experiments in animal models have
hown that the recruitment and incorporation of endothe-
ial progenitor cells can be increased with combinations of
rowth factors and/or cytokines [43], but combining gran-
locyte colony-stimulating factor-induced cell mobilization
ith intramyocardial VEGF injection did not improve heart
unction in humans, despite a signiﬁcant increase in the
umber of circulating endothelial progenitor cells [23]. The
uthors concluded that higher VEGF gene doses and/or the
dministration of combinations of genes might be necessary
o increase endothelial progenitor cell incorporation [44].
lternatively, a single gene that regulates the expression
f multiple angiogenic factors could be administered. For
xample, Shh, which is active during embryonic vasculo-
enesis, upregulates the expression of several angiogenic
ytokines and enhances ventricular function in an animal
odel of myocardial infarction [12].
Like gene therapy, cell-based therapeutic approaches
ave not been completely characterized. Gene and cell ther-
py appear to have commonalities that could be exploited
o enhance the beneﬁt of each individual approach; fur-
hermore, combined gene-cell therapy may be equally or
ven more beneﬁcial at smaller doses than those required
or either individual treatment, which may improve patient
afety. Stem cells could be genetically modiﬁed before
dministration to improve the survival, differentiation and
unctional integration of both transplanted and endogenous
ells, and advances in nanotechnology and tissue engineer-
ng have led to the development of pro-angiogenic matrices
hat deliver locally high concentrations of angiogenic growth
actors or DNA that encodes growth factors [45]. These novel
trategies may enable gene and cell therapy to be combined
n a variety of tissue types for in situ biomedical applica-
ions.
rom the bench to the bedside
variety of biological, technical, methodological and
isease-related factors have hindered the translation of
ene therapy from the research laboratory to the clinic.
n retrospect, the success of gene therapy in animal mod-
ls may have generated unreasonably high expectations for
ts use in a clinical environment. Species-speciﬁc variations
re unavoidable and chronic cardiovascular diseases are
ften polygenetic, so successful treatment with the one-
ime administration of a single gene appears unrealistic,
specially as the disease has progressed for decades in mostJ. Roncalli et al.
atients. The clinical success or failure of gene therapy
s determined by the disease treated and the effective-
ess of the gene itself, as well as the method of delivery
nd the delivery vector. Nonviral vectors are generally con-
idered safe, but their transfection efﬁciency is low and,
onsequently, these vectors are of limited utility for treat-
ents that require long-term expression. Viral vectors are
fﬁciently transfected, but immunogenic and pathogenic
oncerns have prompted research into alternative, novel
irus serotypes. Transfection efﬁciency is likely to increase
s new vectors are identiﬁed, and methods that target
ectors to speciﬁc tissues could also increase therapeu-
ic potency and reduce adverse effects; however, targeted
dministration must overcome yet another set of techni-
al limitations. A precise understanding of the mechanisms
nderlying neovascularization, including the time course
nd sequential roles of angiogenic and trophic factors, will
nable researchers to better mimic the endogenous regen-
rative response.
onclusions
esults from clinical trials suggest that cardiovascular gene
herapy is safe but provides only limited improvements in
lobal cardiovascular variables. However, only a small frac-
ion of potential genetic targets have been investigated in
atients, and large clinical trials of gene therapy for treat-
ent of LVD and heart failure have yet to be completed.
urthermore, angiogenic gene therapy appears to restore
erfusion in ischaemic myocardial tissue, and the transfer
f nonangiogenic genes may correct the defects in calcium
andling that contribute to abnormal contractile function
n patients with heart failure. New genes, combinations of
enes, expression vectors, delivery systems and approaches
hat combine gene and cell therapy continue to be devel-
ped and tested rigorously; collectively, these reﬁnements
romise to improve both patient response and safety.
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